Additional Daily Intramuscular Progesterone for Luteal Phase Support does not Improve Live Birth Rates of Programmed Frozen-Thawed Embryo Transfer Cycles

Yıl 2024, Cilt: 50 Sayı: 2, 177 - 183, 08.10.2024

Kiper Aslan , Işıl Kasapoğlu , Tugba Akkok , Cihan Çakır , Berrin Avcı , Gürkan Uncu

https://doi.org/10.32708/uutfd.1477832

Öz

This retrospective cohort study aims to investigate whether additional daily intramuscular progesterone (IMP) for luteal phase support improves live birth rates of programmed frozen-thawed embryo transfer (FET) cycles. The study was conducted at a tertiary level university hospital assisted reproductive technology (ART) center between January 2014 and Jan 2021. Six hundred four infertile patients with single-day 5-6 frozen-thawed blastocyst embryo transfer were enrolled in the study. All patients received either 8% micronized vaginal gel or vaginal progesterone capsules for luteal phase support. Intramuscular progesterone was added to vaginal progesterone depending on the in vitro fertilization (IVF) specialist’s choice. Luteal phase support (LPS) was started 6 days before transfer in frozen-thawed cycles and continued until the end of the first trimester. Cycles were compared depending on vaginal progesterone types (8% gel vs. capsule) and the presence of intramuscular progesterone. The primary outcome was the live birth rate. A total of 604 FET cycles were enrolled. Using 8% micronized progesterone or progesterone capsules did not change the live birth rates (24% vs. 25.9%). As the main result, intramuscular progesterone support with vaginal progesterone compared with only vaginal progesterone did not improve the live birth results (22% vs. 24%). In conclusion, this study demonstrated that routine IMP progesterone given in combination with vaginal progesterone does not improve ART outcomes. This combination may be beneficial in a selective population with a monitored luteal phase. Using any form of vaginal progesterone alone is adequate for LPS.

Anahtar Kelimeler

Luteal Phase Support, intramuscular progesterone, infertility, vaginal progesterone, intra-cytoplasmic sperm injection

Luteal Faz Desteğinde Günlük Intramuskuler Progesteron İlavesi Donma-Çözme Embriyo Transferi Sikluslarında Canlı Doğum Oranlarını Artırmaz

Öz

Bu retrospektif kohort çalışması, programlanmış dondurulmuş-çözünmüş embriyo transfer (FET) döngülerinde luteal faz desteğinde intramuskuler progesteron eklenmesinin canlı doğum oranlarını arttırıp arttırmadığını araştırmayı amaçlar. Çalışma, Ocak 2014 ile Ocak 2021 arasında üçüncü basamak bir üniversite hastanesinde yardımcı üreme teknolojisi (ART) merkezinde yapıldı. Çalışmaya, teki 5.-6. gün dondurulmuş-çözünmüş blastokist embriyo transferi yapılan 604 infertil hasta dahil edildi. Tüm hastalara luteal faz desteği için ya %8 mikronize vajinal jel ya da vajinal progesteron kapsülleri verildi. İntramusküler progesteron, tüp bebek uzmanının tercihine bağlı olarak vajinal progesterona eklendi. Luteal faz desteği (LPS), dondurulmuş-çözünmüş döngülerde transferden 6 gün önce başlatıldı ve birinci trimesterin sonuna kadar devam etti. Sikluslar, vajinal progesteron tiplerine (8% jel vs. kapsül) ve intramusküler progesteronun varlığına bağlı olarak karşılaştırıldı. Birincil sonuç canlı doğum oranıydı. %8 mikronize progesteron veya progesteron kapsülleri kullanımı canlı doğum oranlarını değiştirmedi (sırasıyla %24 ve %25,9). Ana sonuç olarak, sadece vajinal progesteron yerine vajinal progesteronla birlikte intramusküler progesteron desteği, canlı doğum sonuçlarını iyileştirmedi (%22'ye karşılık %24). Sonuç olarak, bu çalışma rutin olarak verilen intra musküler progesteronun, vajinal progesteronla birlikte verilmesinin ART sonuçlarını iyileştirmediğini göstermektedir. Bu kombinasyon, luteal fazı monitorize edilmiş olan seçili bir popülasyonda faydalı olabilir. Herhangi bir vajinal progesteron formunun tek başına LPS için yeterli olduğu sonucuna varılmıştır.

Anahtar Kelimeler

Luteal Faz Desteği, İnfertilite, İntramuskuler Progesteron, Vajinal Progesteron, İntrasitoplazmik sperm injeksiyonu

Kaynakça

• 1. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update. 2007 Nov-Dec;13(6):581-90.
• 2. Bergquist C, Nillius SJ, Wide L. Human gonadotropin therapy. II. Serum estradiol and progesterone patterns during nonconceptual cycles. Fertil Steril. 1983 Jun;39(6):766-71.
• 3. Howles CM, Macnamee MC, Edwards RG. Follicular development and early luteal function of conception and non- conceptional cycles after human in-vitro fertilization: endocrine correlates. Hum Reprod. 1987 Jan;2(1):17-21.
• 4. Roque M, Haahr T, Geber S, Esteves SC, Humaidan P. Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. Hum Reprod Update. 2019 Jan 1;25(1):2-14.
• 5. Blockeel C, Drakopoulos P, Santos-Ribeiro S, Polyzos NP, Tournaye H. A fresh look at the freeze-all protocol: a SWOT analysis. Hum Reprod. 2016 Mar;31(3):491-7.
• 6. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000 Mar-Apr;6(2):139-48.
• 7. Salehpour S, Saharkhiz N, Nazari L, Sobhaneian A, Hosseini S. Comparison of Subcutaneous and Vaginal Progesterone Used for Luteal Phase Support in Patients Undergoing Intracytoplasmic Sperm Injection Cycles. JBRA Assist Reprod. 2021 Apr 27;25(2):242-245.
• 8. Griesinger G, Blockeel C, Kahler E, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020 Nov 4;15(11):e0241044.
• 9. Khrouf M, Slimani S, Khrouf MR, et al. Progesterone for Luteal Phase Support in In Vitro Fertilization: Comparison of Vaginal and Rectal Pessaries to Vaginal Capsules: A Randomized Controlled Study. Clin Med Insights Womens Health. 2017 Jan 5;9:43-47.
• 10. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas. 1993 May;16(3):185-202.
• 11. Vuong LN, Pham TD, Le KTQ, et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod. 2021 Jun 18;36(7):1821-1831.
• 12. Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertil Steril. 2018 May;109(5):756-762.
• 13. Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016 Aug;48(2):161-70.
• 14. Griesinger G, Tournaye H, Macklon N, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019 Feb;38(2):249-259.
• 15. Aghsa MM, Rahmanpour H, Bagheri M, Davari-Tanha F, Nasr R. A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest(®) when used for luteal phase support in ICSI treatment. Arch Gynecol Obstet. 2012 Oct;286(4):1049-54.
• 16. Serour, A. Luteal Phase Support In Fresh IVF/ICSI Cycles. International Journal of Gynecology & Obstetrics. 2012; 119: S533-S533.
• 17. Tay PY, Lenton EA. The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Med J Malaysia. 2005 Jun;60(2):151-7.
• 18. Lightman A, Kol S, Itskovitz-Eldor J. A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Hum Reprod. 1999 Oct;14(10):2596-9.
• 19. Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015 Mar;186:49-53.
• 20.Cicinelli E, de Ziegler D. Transvaginal progesterone: evidencefor a new functional 'portal system' flowing from the vagina tothe uterus. Hum Reprod Update. 1999 Jul-Aug;5(4):365-72.21.Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C,Hornstein M. Crinone vaginal gel is equally effective and bettertolerated than intramuscular progesterone for luteal phasesupport in in vitro fertilization-embryo transfer cycles: aprospective randomized study. Fertil Steril. 2010Dec;94(7):2596-9.
• 22.Abate A, Brigandi A, Abate FG, Manti F, Unfer V, Perino M.Luteal phase support with 17alpha-hydroxyprogesterone versusunsupported cycles in in vitro fertilization: a comparativerandomized study. Gynecol Obstet Invest. 1999;48(2):78-80.
• 23.Nawroth F, Ludwig M. What is the 'ideal' duration of progesterone supplementation before the transfer ofcryopreserved-thawed embryos in estrogen/progesteronereplacement protocols? Hum Reprod. 2005 May;20(5):1127-34.
• 24.Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L,Sauer MV. Pharmacokinetics and endometrial tissue levels ofprogesterone after administration by intramuscular and vaginalroutes: a comparative study. Fertil Steril. 1994 Sep;62(3):485-90.
• 25.Aboulghar MA, Amin YM, Al-Inany HG, et al. Prospectiverandomized study comparing luteal phase support for ICSIpatients up to the first ultrasound compared with an additionalthree weeks. Hum Reprod. 2008 Apr;23(4):857-62.
• 26.Abdelhakim AM, Abd-El Gawad M, Hussein RS, Abbas AM.Vaginal versus intramuscular progesterone for luteal phasesupport in assisted reproductive techniques: a systematic review and meta-analysis of randomized controlled trials. GynecolEndocrinol. 2020 May;36(5):389-397.
• 27.Van der Linden M, Buckingham K, Farquhar C, Kremer JA,Metwally M. Luteal phase support for assisted reproductioncycles. Cochrane Database Syst Rev. 2015 Jul7;2015(7):CD009154.
• 28.Child T, Leonard SA, Evans JS, Lass A. Systematic review ofthe clinical efficacy of vaginal progesterone for luteal phasesupport in assisted reproductive technology cycles. ReprodBiomed Online. 2018 Jun;36(6):630-645.
• 29.Labarta E, Mariani G, Paolelli S, et al. Impact of low serumprogesterone levels on the day of embryo transfer on pregnancy outcome: a prospective cohort study in artificial cycles withvaginal progesterone. Hum Reprod. 2021 Feb 18;36(3):683-692.
• 30.Labarta E, Mariani G, Holtmann N, Celada P, Remohí J, BoschE.Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2017 Dec 1;32(12):2437-2442.
• 31.Tu J, Lin G, Gong F. Additional luteal support might improveIVF outcomes in patients with low progesterone level in middleluteal phase following a GnRH agonist protocol. GynecolEndocrinol. 2021 Feb;37(2):132-136.
• 32.Alyasin A, Agha-Hosseini M, Kabirinasab M, Saeidi H,Nashtaei MS. Serum progesterone levels greater than32.5 ng/ml on the day of embryo transfer are associated withlower live birth rate after artificial endometrial preparation: aprospective study. Reprod Biol Endocrinol. 2021 Feb18;19(1):24.
• 33.Thomsen LH, Kesmodel US, Erb K, et al. The impact of lutealserum progesterone levels on live birth rates-a prospectivestudy of 602 IVF/ICSI cycles. Hum Reprod. 2018 Aug1;33(8):1506-1516.
• 34.Boynukalin FK, Gultomruk M, Turgut E, et al. Measuring theserum progesterone level on the day of transfer can be anadditional tool to maximize ongoing pregnancies in singleeuploid frozen blastocyst transfers. Reprod Biol Endocrinol.2019 Nov 29;17(1):102.
• 35.Melo P, Chung Y, Pickering O, et al. Serum luteal phaseprogesterone in women undergoing frozen embryo transfer inassisted conception: a systematic review and meta-analysis. Fertil Steril. 2021 Aug 10:S0015-0282(21)00577-X.
• 36.Devine K, Richter KS, Widra EA, McKeeby JL. Vitrified blastocyst transfer cycles with the use of only vaginalprogesterone replacement with Endometrin have inferiorongoing pregnancy rates: results from the planned interimanalysis of a three-arm randomized controlled noninferioritytrial. Fertil Steril. 2018 Feb;109(2):266-275.
• 37.Devine K, Richter KS, Jahandideh S, Widra EA, McKeeby JL.Intramuscular progesterone optimizes live birth fromprogrammed frozen embryo transfer: a randomized clinicaltrial. Fertil Steril. 2021 May 12:S0015-0282(21)00298-3.
• 38.Polat M, Mumusoglu S, Bozdag G, Ozbek IY, Humaidan P,Yarali H. Addition of intramuscular progesterone to vaginalprogesterone in hormone replacement therapy in vitrified-warmed blastocyst transfer cycles. Reprod Biomed Online.2020 Jun;40(6):812-818.
• 39.Elgindy E, Elsedeek MS. Day 5 expanded blastocyststransferred on same day have comparable outcome to those leftfor more extended culture and transferred on day 6. J AssistReprod Genet. 2012 Oct;29(10):1111-5.